Details
Stereochemistry | ACHIRAL |
Molecular Formula | C12H16N2O |
Molecular Weight | 204.2682 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN(C)CCC1=CNC2=C1C=C(O)C=C2
InChI
InChIKey=VTTONGPRPXSUTJ-UHFFFAOYSA-N
InChI=1S/C12H16N2O/c1-14(2)6-5-9-8-13-12-4-3-10(15)7-11(9)12/h3-4,7-8,13,15H,5-6H2,1-2H3
CNS Activity
Sources: https://www.ncbi.nlm.nih.gov/pubmed/24650558
Curator's Comment: referenced study was conducted in rat
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: Q64264 Gene ID: 15550.0 Gene Symbol: Htr1a Target Organism: Mus musculus (Mouse) Sources: https://www.ncbi.nlm.nih.gov/pubmed/25446678 |
|||
Target ID: P35363 Gene ID: 15558.0 Gene Symbol: Htr2a Target Organism: Mus musculus (Mouse) Sources: https://www.ncbi.nlm.nih.gov/pubmed/25446678 |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Primary | Unknown Approved UseUnknown |
PubMed
Title | Date | PubMed |
---|---|---|
Bufotenine reconsidered as a diagnostic indicator of psychiatric disorders. | 1995 Nov 27 |
|
Functional and radioligand binding characterization of rat 5-HT6 receptors stably expressed in HEK293 cells. | 1997 Apr-May |
|
Altered consciousness states and endogenous psychoses: a common molecular pathway? | 1997 Dec 19 |
|
Molecular basis of partial agonism: orientation of indoleamine ligands in the binding pocket of the human serotonin 5-HT2A receptor determines relative efficacy. | 2003 Jan |
|
Evaluation of the ocular hypotensive response of serotonin 5-HT1A and 5-HT2 receptor ligands in conscious ocular hypertensive cynomolgus monkeys. | 2003 Jul |
|
Urinary excretion of dietary contaminants in horses. | 2006 Aug |
|
New indole N-oxide alkaloids from Evodia fargesii. | 2006 Feb |
|
Lack of bufadienolides in the skin secretion of red bellied toads, Melanophryniscus spp. (Anura, Bufonidae), from Uruguay. | 2007 Jan |
|
Liquid chromatography-tandem mass spectrometry method for the simultaneous analysis of multiple hallucinogens, chlorpheniramine, ketamine, ritalinic acid, and metabolites, in urine. | 2007 Oct |
|
Indolealkylamines: biotransformations and potential drug-drug interactions. | 2008 Jun |
|
Early onset muscarinic manifestations after wild mushroom ingestion. | 2008 Sep |
|
Sudden death associated with intravenous injection of toad extract. | 2009 Jul 1 |
|
Elevated urine levels of bufotenine in patients with autistic spectrum disorders and schizophrenia. | 2010 |
|
Effects of monoamine oxidase inhibitor and cytochrome P450 2D6 status on 5-methoxy-N,N-dimethyltryptamine metabolism and pharmacokinetics. | 2010 Jul 1 |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25446678
Curator's Comment: referenced study was conducted on mice.
Age-matched wild-type FVB/N and Tg-CYP2D6 mice were given an intraperitoneal dose of either harmaline 90, 2, 5, or 15 mg/kg) or bufotenine (0, 2, 10 0r 20 mg/kg). Wild-type and Tg-CYP2D6 mice exhibited hyperthermia with high doses of bufotenine ( 10 and 20 mg/kg).
Route of Administration:
Intraperitoneal
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/2706543
To determine if serotonin is involved in associative conditioning-produced changes of Type B photo-receptors, isolated nervous systems were exposed to a conditioning procedure in the absence or presence of drugs that alter normal serotonergic neurotransmission. Nervous systems were dissected, mounted and treated with protease before washing with artificial seawater (ASW), or ASW containing 100 microM bufotenine. When treated bufotenine clearly reduced the pairing specific cumulative depolarization and changes in input resistance. Treatment involving bufotenine suggests that serotonin modulates Type B photoreceptor excitability during associative conditioning.
Name | Type | Language | ||
---|---|---|---|---|
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Code | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
DEA NO. |
7433
Created by
admin on Fri Dec 15 18:48:41 GMT 2023 , Edited by admin on Fri Dec 15 18:48:41 GMT 2023
|
||
|
WIKIPEDIA |
TiHKAL
Created by
admin on Fri Dec 15 18:48:41 GMT 2023 , Edited by admin on Fri Dec 15 18:48:41 GMT 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
89593
Created by
admin on Fri Dec 15 18:48:41 GMT 2023 , Edited by admin on Fri Dec 15 18:48:41 GMT 2023
|
PRIMARY | |||
|
DB01445
Created by
admin on Fri Dec 15 18:48:41 GMT 2023 , Edited by admin on Fri Dec 15 18:48:41 GMT 2023
|
PRIMARY | |||
|
10257
Created by
admin on Fri Dec 15 18:48:41 GMT 2023 , Edited by admin on Fri Dec 15 18:48:41 GMT 2023
|
PRIMARY | |||
|
BUFOTENIN
Created by
admin on Fri Dec 15 18:48:41 GMT 2023 , Edited by admin on Fri Dec 15 18:48:41 GMT 2023
|
PRIMARY | |||
|
0A31347TZK
Created by
admin on Fri Dec 15 18:48:41 GMT 2023 , Edited by admin on Fri Dec 15 18:48:41 GMT 2023
|
PRIMARY | |||
|
DTXSID0048894
Created by
admin on Fri Dec 15 18:48:41 GMT 2023 , Edited by admin on Fri Dec 15 18:48:41 GMT 2023
|
PRIMARY | |||
|
m2753
Created by
admin on Fri Dec 15 18:48:41 GMT 2023 , Edited by admin on Fri Dec 15 18:48:41 GMT 2023
|
PRIMARY | Merck Index | ||
|
207-667-9
Created by
admin on Fri Dec 15 18:48:41 GMT 2023 , Edited by admin on Fri Dec 15 18:48:41 GMT 2023
|
PRIMARY | |||
|
3210
Created by
admin on Fri Dec 15 18:48:41 GMT 2023 , Edited by admin on Fri Dec 15 18:48:41 GMT 2023
|
PRIMARY | |||
|
487-93-4
Created by
admin on Fri Dec 15 18:48:41 GMT 2023 , Edited by admin on Fri Dec 15 18:48:41 GMT 2023
|
PRIMARY |
ACTIVE MOIETY
METABOLITE (PARENT)
PARENT (METABOLITE ACTIVE)
SALT/SOLVATE (PARENT)